×
About 2,260 results

ALLMedicine™ Adrenocortical Carcinoma Center

Research & Reviews  815 results

68Ga-DOTA.SA.FAPI as a Potential, Noninvasive Diagnostic Probe for Recurrent and Metast...
https://doi.org/10.1097/RLU.0000000000004563
Clinical Nuclear Medicine; Chopra S, Walia R et. al.

Feb 3rd, 2023 - Metastatic or recurrent adrenocortical carcinoma (ACC) is a potentially fatal malignancy, which poses major challenges in disease management owing to lack of effective systemic therapies. The drastically reduced survival rates require prompt ident...

BMAL1 collaborates with CLOCK to directly promote DNA double-strand break repair and tu...
https://doi.org/10.1038/s41388-023-02603-y
Oncogene Zhang C, Chen L et. al.

Feb 2nd, 2023 - Accumulating evidence indicates a correlation between circadian dysfunction and genomic instability. However, whether the circadian machinery directly regulates DNA damage repair, especially in double-strand breaks (DSBs), remains poorly understoo...

Inflammation-based scores as predictors of treatment response in advanced adrenocortica...
https://doi.org/10.1530/ERC-22-0372
Endocrine-related Cancer; Mangone A, Altieri B et. al.

Jan 31st, 2023 - Treatment for advanced adrenocortical carcinoma (ACC) consists of mitotane alone or combined with etoposide, doxorubicin and cisplatin (EDP). Although both therapies are widely used, markers of response are still lacking. Since inflammation-based ...

Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
https://clinicaltrials.gov/ct2/show/NCT04358107

Jan 23rd, 2023 - Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 mon...

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
https://clinicaltrials.gov/ct2/show/NCT05237934

Jan 23rd, 2023 - Background: Neuroendocrine neoplasms (NENs) are divided into neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These are rare malignancies occurring for example in the gastrointestinal tract, islets of the pancreas, lung, adrenal ...

see more →

Guidelines  3 results

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021,...
https://doi.org/10.6004/jnccn.2021.0001
Journal of the National Comprehensive Cancer Network : JN... Daly MB, Pal T et. al.

Jan 7th, 2021 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and r...

Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practi...
https://doi.org/10.1530/EJE-16-0467
European Journal of Endocrinology; Fassnacht M, Arlt W et. al.

Jul 9th, 2016 - : By definition, an adrenal incidentaloma is an asymptomatic adrenal mass detected on imaging not performed for suspected adrenal disease. In most cases, adrenal incidentalomas are nonfunctioning adrenocortical adenomas, but may also represent con...

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an end...
https://doi.org/10.1210/jc.2008-0104
The Journal of Clinical Endocrinology and Metabolism; Funder JW, Carey RM et. al.

Jun 17th, 2008 - Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism. The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, si...

see more →

Clinicaltrials.gov  48 results

Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
https://clinicaltrials.gov/ct2/show/NCT04358107

Jan 23rd, 2023 - Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 mon...

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
https://clinicaltrials.gov/ct2/show/NCT05237934

Jan 23rd, 2023 - Background: Neuroendocrine neoplasms (NENs) are divided into neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These are rare malignancies occurring for example in the gastrointestinal tract, islets of the pancreas, lung, adrenal ...

Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)
https://clinicaltrials.gov/ct2/show/NCT04447014

Jan 17th, 2023 - Background: Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75-90% and an average survival from the time of diagnosis o...

Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma
https://clinicaltrials.gov/ct2/show/NCT05660889

Dec 21st, 2022 - The goal of this observational pilot study is to explore whether we can identify biomarkers predictive for the diagnosis of adrenocortical carcinoma in blood. Five participants who are suspected to have adrenocortical carcinoma will undergo an adr...

Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma
https://clinicaltrials.gov/ct2/show/NCT04318730

Dec 19th, 2022 - Adrenocortical carcinoma (ACC) is a rare aggressive malignant tumor. According to the literature, the 5-year survival rate of ACC is 12%-47%. For patients with advanced ACC, mitotane alone or combined with traditional chemotherapy was the first-li...

see more →

News  34 results

New Adrenalectomy Guidelines Cover Surgery, Multispecialty Care
https://www.medscape.com/viewarticle/979619

Aug 23rd, 2022 - New adrenalectomy guidelines from the American Association of Endocrine Surgeons are aimed at assisting both specialist and general surgeons with perioperative adrenal care, including guidance on management of adrenal incidentalomas. Published onl...

Adjuvant Mitotane Fails to Improve RFS in Patients with ACC at Low/Intermediate Risk of Recurrence
https://www.onclive.com/view/adjuvant-mitotane-fails-to-improve-rfs-in-patients-with-acc-at-low-intermediate-risk-of-recurrence

Feb 20th, 2022 - The utilization of mitotane (Lysodren) in the adjuvant setting did not produce significant benefit for patients with adrenocortical carcinoma (ACC) at low or intermediate risk of recurrence, according to findings from the phase 3 ADIUVO trial (NCT...

Investigational PI3K-γ Inhibitor Eganelisib Plus Nivolumab Elicits Early Efficacy in Head and Neck Cancer, Melanoma
https://www.onclive.com/view/investigational-pi3k--inhibitor-eganelisib-plus-nivolumab-elicits-early-efficacy-in-head-and-neck-cancer-melanoma

Oct 6th, 2021 - Treatment with the combination of eganelisib (IPI-549), a selective PI3K-γ inhibitor, and nivolumab (Opdivo) demonstrated encouraging clinical activity and a favorable safety profile in patients with head and neck squamous cell carcinoma (HNSCC), ...

Exceptional Responder Provides Treatment Clues in Bladder Cancer
https://www.onclive.com/view/exceptional-responder-provides-treatment-clues-in-bladder-cancer

Oct 6th, 2021 - Nikhil Wagle, MD An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib (Votrient), according to r...

Dr. McGregor on Immunotherapy in Rare Genitourinary Cancers
https://www.onclive.com/view/dr-mcgregor-on-immunotherapy-in-rare-genitourinary-cancers

Oct 6th, 2021 - Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses immunotherapy in rare genitourinary (GU) cancers. Clinical trials are generally geared to...

see more →

Patient Education  4 results see all →